Lmr Partners LLP Aldeyra Therapeutics, Inc. Transaction History

Lmr Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.77 - $9.93 $3,571 - $6,146	-619 Reduced 2.36%	25,585 $254,000
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $45,176 - $63,051	8,893 Added 51.37%	26,204 $182,000
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $42,065 - $83,958	17,311 New	17,311 $69,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $9.63 $184,348 - $507,221	-52,671 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $1.75 Million - $2.49 Million	-220,184 Reduced 80.7%	52,671 $462,000
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $2.61 Million - $3.72 Million	250,175 Added 1103.06%	272,855 $3.09 Million
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $148,100 - $327,045	22,680 New	22,680 $269,000
Q3 2020 Nov 16, 2020	SELL	$4.0 - $7.53 $42,160 - $79,366	-10,540 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $20,763 - $53,227	10,540 New	10,540 $44,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.